Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 06:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
T-Cell Depleted Double UCB for Refractory AML
NCT01464359 · Masonic Cancer Center, University of Minnesota · PHASE2 · terminated · last registry update 2017-12-28 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Slow accrual” | – | Registry record, Masonic Cancer Center, University of Minnesota |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against XDH within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2018-06-14Results posted on the registry: Takeda, Febuxostat + Allopurinol (NCT01101035)
- 2018-04-13Results posted on the registry: Cedars-Sinai Medical Center, Allopurinol (NCT00643123)
- 2018-02-22Results posted on the registry: Cedars-Sinai Medical Center, Allopurinol (NCT00732251)
- 2018-01-30Results posted on the registry: Ardea Biosciences, Inc., lesinurad + lesinurad (NCT01808144)
- 2018-01-23Results posted on the registry: Ardea Biosciences, Inc., RDEA3170 2.5 mg + allopurinol 300 mg (NCT02498652)
- 2018-01-12Also stopped (terminated): University of Mississippi Medical Center, febuxostat (NCT01701622)
- 2018-01-09Also stopped (terminated): Roswell Park Cancer Institute, rasburicase + allopurinol (NCT01564277)
- 2017-12-28Also stopped (terminated): Masonic Cancer Center, University of Minnesota, Allopurinol + Cyclophosphamide (NCT00652899)
- 2017-12-27Results posted on the registry: Landspitali University Hospital, Allopurinol + Febuxostat (NCT02752633)
- 2017-12-20Results posted on the registry: Ardea Biosciences, Inc., RDEA3170 10 mg + allopurinol 300 mg (NCT02279641)
- 2017-12-13Phase 3 first posted: Mochida Pharmaceutical Company, Ltd., FYU-981 + Febuxostat (NCT03372200)
- 2017-12-08Results posted on the registry: Roswell Park Cancer Institute, rasburicase + allopurinol (NCT01564277)
- 2017-09-27Also stopped (terminated): OHSU Knight Cancer Institute, anti-thymocyte globulin + filgrastim (NCT00281879)
- 2017-09-13Also stopped (withdrawn): National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Placebo + Allopurinol (NCT00288171)
- 2017-08-03Also stopped (terminated): Yokohama City University Medical Center, Febuxostat (NCT02279342)
- 2017-07-27Results posted on the registry: Ardea Biosciences, Inc., RDEA3170 15 mg + RDEA3170 10 mg (NCT02246673)
- 2017-07-18Results posted on the registry: Regeneron Pharmaceuticals, Rilonacept + Placebo (NCT01459796)
- 2017-07-18Also stopped (terminated): Regeneron Pharmaceuticals, Rilonacept + Placebo (NCT01459796)
- 2017-06-29Results posted on the registry: Brigham and Women's Hospital, Vitamin D ergocalciferol + Probenecid (NCT01320722)
- 2017-05-22Phase 3 first posted: University Hospital Tuebingen, Allopurinol + Mannitol (NCT03162653)
- 2017-05-12Phase 3 first posted: Alliance for Clinical Trials in Oncology, Allopurinol + Cytarabine (NCT03150693)
- 2017-05-11Also stopped (withdrawn): Université de Sherbrooke, allopurinol (NCT01775098)
- 2017-05-02Results posted on the registry: Regeneron Pharmaceuticals, Rilonacept (NCT00610363)
- 2017-04-28Results posted on the registry: Regeneron Pharmaceuticals, Rilonacept + Indomethacin (NCT00855920)
- 2017-04-28Results posted on the registry: Regeneron Pharmaceuticals, Rilonacept (NCT00856206)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision